Comparative Pharmacology
Head-to-head clinical analysis: ENPRESSE 28 versus PORTIA 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENPRESSE 28 versus PORTIA 21.
ENPRESSE-28 vs PORTIA-21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ENPRESSE-28 is a combined hormonal contraceptive containing ethinyl estradiol and desogestrel. It acts by suppressing gonadotropin release (FSH and LH) from the pituitary, inhibiting ovulation, thickening cervical mucus to impede sperm penetration, and altering the endometrium.
Oral contraceptive: inhibition of ovulation by suppressing gonadotropin release; increases viscosity of cervical mucus, reducing sperm penetration; alters endometrial receptivity.
1 tablet (ethinyl estradiol 0.035 mg / norgestimate 0.25 mg) orally once daily for 21 days, followed by 7 placebo days.
One tablet (norgestimate 0.180 mg/ethinyl estradiol 0.035 mg) orally once daily for 21 days, followed by 7 days of placebo.
None Documented
None Documented
Terminal elimination half-life is 18-24 hours, allowing once-daily dosing; steady-state achieved within 5-7 days.
Terminal elimination half-life: 24-30 hours; clinical context: steady-state reached after 5-7 days, allows once-daily dosing
Primarily renal excretion as unchanged drug (70-80%) and glucuronide conjugate (15-20%); biliary/fecal elimination accounts for <5%.
Renal (50-60% unchanged), fecal (30-40% as metabolites), minor biliary
Category C
Category C
Oral Contraceptive
Oral Contraceptive